Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafolecimab plus PD-1 inhibitor with neoadjuvant chemoradiotherapy for pMMR/MSS locally advanced rectal cancer
ChiCTR2600131840Phase 4Not yet recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tafolecimab in rectal adenocarcinoma (2 arms), sponsored by Guangdong Provincial People's Hospital. Primary endpoints: Pathological complete response rate and Clinical complete response rate. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
tafolecimab
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600131840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131840.